Shares in Eli Lilly and Company do not show any sign of a slowdown in the ascending dynamic. Investors could bet on a continuation of the underlying trend. Investors have an opportunity to buy the stock and target the $ 169.13.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Eli Lilly And Company accounts for 4.45 % of our USA Portfolio. A trade is currently open since 06/30/2020 with a purchase price of $ 162.51. Discover the other 19 stocks of the USA portfolio managed by the MarketScreener portfolio management team.
The share is getting closer to its long-term support in weekly data, at USD 141.46, which offers good timing for buyers.
Graphically speaking, the timing seems perfect for purchasing the stock close to the USD 141.52 support.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
The stock is in a well-established, long-term rising trend above the technical support level at 141.46 USD
Based on current prices, the company has particularly high valuation levels.
The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.